Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Single psilocybin dose linked to increased social exploration in OCD mouse model (opens in a new tab)

medicalxpress.com · 2026-10-01

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Four of five claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 4 supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe study used 91 mice, including SAPAP3 knockout mice and littermate controls, and compared a single psilocybin injection with saline.View evidenceHide evidence

As stated91 mice

Why this verdict

The abstract-level profile verifies the use of SAPAP3 knockout mice, wild-type littermate controls, and single psilocybin injection versus a control condition, but it explicitly says the abstract does not report sample sizes. The specific number of 91 mice and the saline-control detail are therefore not verifiable from the supplied abstract-depth paper profile.

1

Study evidence

A single 1 mg/kg i.p. dose of psilocybin produced an enduring restoration of novel-mouse-directed investigation in male SAPAP3 knockout mice when tested 7 days post-injection.

“Male and female SAPAP3 KO mice and wild-type littermates received a 1 mg/kg psilocybin intraperitoneal injection, and social behavior was assessed seven days later using the three-chamber social interaction test.”
Claim 2 of 5SupportedA single dose of psilocybin was linked to greater social exploration in male mice exhibiting OCD-like behaviors.View evidenceHide evidence

Why this verdict

The abstract-level evidence supports that a single 1 mg/kg psilocybin injection produced a male-specific, enduring restoration of novel-mouse-directed investigation/social novelty behavior in SAPAP3 knockout mice. The headline uses associational language (“was linked to”) and does not exceed the supplied evidence.

1

Study evidence

A single 1 mg/kg i.p. dose of psilocybin produced an enduring restoration of novel-mouse-directed investigation in male SAPAP3 knockout mice when tested 7 days post-injection.

“Male and female SAPAP3 KO mice and wild-type littermates received a 1 mg/kg psilocybin intraperitoneal injection, and social behavior was assessed seven days later using the three-chamber social interaction test.”
Claim 3 of 5SupportedResearchers investigated the effects of psilocybin on a mouse model of obsessive-compulsive disorder.View evidenceHide evidence

Why this verdict

The paper profile says the study tested psilocybin in SAPAP3 knockout mice, described as an OCD-model with compulsive-like behavior and social abnormalities. The claim accurately frames this as investigation in a mouse model rather than in humans.

1

Study evidence

A single 1 mg/kg i.p. dose of psilocybin produced an enduring restoration of novel-mouse-directed investigation in male SAPAP3 knockout mice when tested 7 days post-injection.

“Male and female SAPAP3 KO mice and wild-type littermates received a 1 mg/kg psilocybin intraperitoneal injection, and social behavior was assessed seven days later using the three-chamber social interaction test.”
Claim 4 of 5SupportedA week after psilocybin was administered, male mice spent more time investigating an unfamiliar mouse.View evidenceHide evidence

As stateda week later

Why this verdict

The paper profile states that social behavior was assessed seven days after injection and that psilocybin restored novel-mouse-directed investigation in male SAPAP3 knockout mice. The claim is consistent with the reported 7-day post-treatment behavioral finding, assuming the surrounding story context limits the mice to the OCD-model males.

1

Study evidence

A single 1 mg/kg i.p. dose of psilocybin produced an enduring restoration of novel-mouse-directed investigation in male SAPAP3 knockout mice when tested 7 days post-injection.

“Male and female SAPAP3 KO mice and wild-type littermates received a 1 mg/kg psilocybin intraperitoneal injection, and social behavior was assessed seven days later using the three-chamber social interaction test.”
Claim 5 of 5SupportedPsilocybin increased c-Fos levels in the medial prefrontal cortex and hippocampus, and infralimbic c-Fos levels correlated with improved social recognition/novelty behavior in male SAPAP3 knockout mice.View evidenceHide evidence

Why this verdict

The profile reports increased c-Fos immunoreactivity in medial prefrontal cortex and hippocampus regardless of genotype, and a correlation between infralimbic c-Fos levels and improved social recognition/novelty behavior in male SAPAP3 knockout mice. The claim correctly frames the infralimbic result as correlational rather than causal.

1

Study evidence

A single 1 mg/kg i.p. dose of psilocybin produced an enduring restoration of novel-mouse-directed investigation in male SAPAP3 knockout mice when tested 7 days post-injection.

“Male and female SAPAP3 KO mice and wild-type littermates received a 1 mg/kg psilocybin intraperitoneal injection, and social behavior was assessed seven days later using the three-chamber social interaction test.”
2

Study evidence

Psilocybin increased c-Fos immunoreactivity in the medial prefrontal cortex and hippocampus regardless of genotype.

“Immunohistochemical quantification of c-Fos revealed that psilocybin increased neural activation in the medial prefrontal cortex and hippocampus regardless of genotype.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Negative regional c-Fos findings: psilocybin did not alter c-Fos in nucleus accumbens, basolateral amygdala, or dorsal striatum.

    The supplied story claims mention the positive mPFC/hippocampal and infralimbic findings but do not report the abstract’s negative c-Fos findings in other regions.

    From c-Fos IHC ROI analysis

  • Evidence-detail limitation at abstract depth: the abstract does not report sample sizes, detailed statistics, or effect-size estimates for the behavioral or c-Fos outcomes.

    The story presentation gives a specific sample size claim and reports findings without noting that the supplied abstract-level evidence lacks sample sizes, detailed statistics, and effect sizes. This limits verification at the requested evidence depth.

    From In vivo mouse pharmacology and behavioral assay; c-Fos IHC ROI analysis

6 things the story did carry across
  • Primary behavioral finding: a single psilocybin dose produced an enduring, male-specific restoration of novel-mouse-directed social recognition/novelty investigation in SAPAP3 knockout mice tested 7 days after injection.
  • Study population and model: SAPAP3 knockout mice and wild-type littermate controls, with sex-stratified assessment in male and female mice.
  • Mechanistic/biomarker finding: psilocybin increased c-Fos in medial prefrontal cortex and hippocampus, and infralimbic c-Fos correlated with behavioral improvement in male SAPAP3 knockout mice.
  • Translational limitation: findings are from a mouse genetic model and may not directly generalize to people with OCD.
  • Sex-specific limitation: behavioral rescue was reported in males and not females.
  • Causality limitation for brain–behavior relation: infralimbic c-Fos association is correlational and does not establish that infralimbic activation caused behavioral improvement.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalTest whether psilocybin produces an enduring rescue of social novelty/recognition behavior in SAPAP3 knockout (OCD-model) mice, including sex-specific effects.In vivo mouse pharmacology and behavioral assayExpand

In plain English

In SAPAP3 knockout and wild-type littermate mice, a single intraperitoneal psilocybin dose (1 mg/kg) produced an enduring, male-specific restoration of novel-mouse-directed investigation in a three-chamber social recognition/novelty test assessed seven days after injection. Psilocybin increased c-Fos immunoreactivity in medial prefrontal cortex and hippocampus irrespective of genotype; infralimbic c-Fos levels correlated with behavioral improvement in male SAPAP3 KO mice. No psilocybin-induced c-Fos changes were reported in nucleus accumbens, basolateral amygdala, or dorsal striatum.

Key findings

  • A single 1 mg/kg i.p. dose of psilocybin produced an enduring restoration of novel-mouse-directed investigation in male SAPAP3 knockout mice when tested 7 days post-injection.
  • Psilocybin increased c-Fos immunoreactivity in medial prefrontal cortex and hippocampus regardless of genotype.
“Male and female SAPAP3 KO mice and wild-type littermates received a 1 mg/kg psilocybin intraperitoneal injection, and social behavior was assessed seven days later using the three-chamber social interaction test.”
What this piece can’t prove
  • Abstract does not report sample sizes, detailed statistics, or effect-size estimates for behavioral or c-Fos outcomes.
  • Behavioral endpoint reported at a single post-treatment timepoint (7 days); temporal profile before or after this point not described in abstract.
  • Findings are from a mouse genetic model (SAPAP3 KO), which may limit direct generalizability to human OCD without additional translational evidence.
2ex vivo animalMap psilocybin-evoked neural activation across prefrontal–hippocampal and other regions using c-Fos immunohistochemistry, and relate neural activation to behavioral rescue.c-Fos IHC ROI analysisExpand

In plain English

In male and female SAPAP3 knockout and wild-type mice given a single 1 mg/kg intraperitoneal psilocybin injection, ex vivo immunohistochemical quantification of the immediate-early gene product c-Fos showed increased activation in the medial prefrontal cortex (mPFC) and hippocampus regardless of genotype, no change in nucleus accumbens, basolateral amygdala, or dorsal striatum, and a specific correlation between infralimbic c-Fos levels and improved social recognition/novelty behavior in male SAPAP3 knockout mice.

Key findings

  • Psilocybin increased c-Fos immunoreactivity in the medial prefrontal cortex and hippocampus regardless of genotype.
  • Psilocybin did not alter c-Fos levels in the nucleus accumbens, basolateral amygdala, or dorsal striatum.
“Immunohistochemical quantification of c-Fos revealed that psilocybin increased neural activation in the medial prefrontal cortex and hippocampus regardless of genotype.”
What this piece can’t prove
  • Abstract lacks details on timing of tissue collection relative to psilocybin dosing, quantitative methods (e.g., cell counts per area), sample sizes, and statistical tests.
  • c-Fos IHC provides an indirect marker of activation and does not identify specific neuronal subtypes or causal mechanisms.
  • Reported correlations are observational and limited to a subgroup (male SAPAP3 KOs), restricting inference about generalizability and causality.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 34 candidate papers

And 28 more candidates considered.